RPG Life Sciences Ltd

BSE: 532983

41

total announcements

RPGLIFE.NS · 15 min delayed

Key Stats · Yahoo Finance · as of 15 Oct 2026

Market Cap

₹4,661 Cr

P/E (TTM)

39.0

P/E (Forward)

29.9

EPS (TTM)

₹72.34

52W Low

₹1,733.00

52W High

₹3,127.80

Dividend Yield

0.86%

Beta

-0.13

Price / Book

7.7

Debt / Equity

3.3

Revenue (TTM)

₹734 Cr

Gross Margin

63.81%

Operating Margin

19.11%

BSECompany UpdateMgmt Change15 Aug 2026

RPG Life Sciences Ltd

Resignation of Senior Management Personnel

RPG Life Sciences Ltd announced the resignation of Mr. Deepak Shukla, Chief Executive - API Business, effective August 14, 2026, due to his appointment as Chief Executive Officer of RPG Active Pharma Limited, a wholly-owned subsidiary.

Read more →📎 1 attachment
BSECompany Update31 Jul 2026

RPG Life Sciences Ltd

Newspaper advertisement in respect to Special window opened for lodgement of transfer and dematerialization request(s).

RPG Life Sciences Ltd has announced a special window for lodgement of transfer and dematerialization requests for physical securities sold/purchased prior to April 1, 2019. The company has published newspaper advertisements in Business Standard and Mumbai Lakshadeep on July 31, 2026, as per SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026. The information will also be hosted on the company's website.

Read more →📎 1 attachment
BSECompany Update▲ PositiveExpansion29 Jul 2026

RPG Life Sciences Ltd

Press Release

RPG Life Sciences Ltd has announced a strategic API initiative to accelerate its next phase of growth. The company will transfer its API business to a wholly owned subsidiary, RPG Active Pharma, and raise an initial amount of up to INR 243 crore from funds managed by InvAscent. RPG Active Pharma will also acquire 100% equity share capital of Actis Generics Private Limited.

Read more →📎 1 attachment
BSECompany UpdateDivestiture29 Jul 2026

RPG Life Sciences Ltd

Execution of Share Purchase Agreement

RPG Life Sciences Ltd has announced the execution of a Business Transfer Agreement for the sale of its Active Pharmaceutical Ingredients (API) business to its wholly-owned subsidiary, RPG Active Pharma Limited, for Rs. 33.55 crore. The sale is expected to be completed by September 30, 2026, subject to customary conditions.

Read more →📎 1 attachment
BSECompany UpdateM&A29 Jul 2026

RPG Life Sciences Ltd

Execution of Business Transfer Agreement

RPG Life Sciences Ltd has executed a Business Transfer Agreement for the sale of its Active Pharmaceutical Ingredients (API) business to its wholly owned subsidiary, RPG Active Pharma Limited, for a consideration of Rs. 33.55 crore. The sale is expected to be completed by September 30, 2026.

Read more →📎 1 attachment
BSECompany UpdateDivestiture29 Jul 2026

RPG Life Sciences Ltd

Outcome of Board Meeting held today July 29, 2026

RPG Life Sciences Ltd has announced the outcome of its board meeting, where it approved the execution of a business transfer agreement for the sale of its API business to its wholly-owned subsidiary, RPG Active Pharma Limited, for a consideration of Rs. 33.55 crore. The sale is expected to be completed by September 30, 2026.

Read more →📎 1 attachment
BSECompany UpdateResults29 Jul 2026

RPG Life Sciences Ltd

Copy of Newspaper Publication

RPG Life Sciences Ltd has published unaudited financial results for the quarter ended June 30, 2026, in newspapers and on its website. The company has also announced a special window for re-lodging transfer requests of physical shares, as per SEBI's circular.

Read more →📎 1 attachment
BSECompany UpdateResults28 Jul 2026

RPG Life Sciences Ltd

Investor Presentation

RPG Life Sciences Ltd has released an investor presentation for its unaudited financial results for the quarter ended June 30, 2026. The presentation highlights the company's Q1 FY27 performance, including historical profit and loss numbers for certain sales divisions. The company operates in the pharmaceutical segment and has a strong global presence.

Read more →📎 1 attachment
BSECompany Update▲ PositiveResults28 Jul 2026

RPG Life Sciences Ltd

Press release

RPG Life Sciences Ltd reported Q1 FY27 financial results with revenue growth of 15.8% and EBITDA growth of 17.9%, with EBITDA margin expanding to 24.5%. The company's Domestic Formulations business outperformed the Indian pharma market growth rate, growing at 14.8%. The company also entered the Top 50 Indian Pharma Companies list in June 2026.

Read more →📎 1 attachment
BSEResultResults28 Jul 2026

RPG Life Sciences Ltd

Unaudited consolidated and standalone Financial Results for quarter ended June 2026

RPG Life Sciences Ltd has announced its unaudited consolidated and standalone financial results for the quarter ended June 30, 2026. The company's revenue from operations was Rs. 19,569 lakhs, with total income of Rs. 19,985 lakhs. Expenses include cost of materials consumed, purchases of stock-in-trade, changes in inventories, employee benefits expense, and finance cost.

Read more →📎 1 attachment
BSEBoard MeetingResults28 Jul 2026

RPG Life Sciences Ltd

Outcome of Board meeting

RPG Life Sciences Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, with revenue from operations at Rs. 19,569 lakhs and total income at Rs. 19,985 lakhs. The company's board of directors has approved the results, and the independent auditor's review report is also attached.

Read more →📎 1 attachment
BSECompany UpdateMgmt Change27 Jul 2026

RPG Life Sciences Ltd

Completion of term of Ms. Zahabiya Khorakiwala

RPG Life Sciences Ltd has announced the completion of the second consecutive five-year term of Ms. Zahabiya Khorakiwala as an Independent Director, effective July 26, 2026. The Sustainability and Corporate Social Responsibility Committee has been reconstituted with new members.

Read more →📎 1 attachment
BSEAGM/EGMResults23 Jul 2026

RPG Life Sciences Ltd

Voting Results along with a copy of Scrutinizer''s Report

RPG Life Sciences Ltd held its Nineteenth Annual General Meeting (AGM) on July 23, 2026, where all resolutions were passed with requisite majority. The meeting was conducted through video conferencing, and the voting results were disclosed. The company provided the facility of remote e-voting and e-voting at the AGM.

Read more →📎 1 attachment
BSEAGM/EGMResults23 Jul 2026

RPG Life Sciences Ltd

19th AGM Proceedings

RPG Life Sciences Ltd held its 19th AGM on July 23, 2026, where all resolutions were passed with a majority. The company declared a 300% dividend of ₹24 per equity share. The meeting was conducted through video conferencing and e-voting was facilitated for members who did not attend in person.

Read more →📎 1 attachment
BSEBoard MeetingResults21 Jul 2026

RPG Life Sciences Ltd

RPG Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/07/2026 ,inter alia, to consider and approve Pursuant to the provisions ....

RPG Life Sciences Ltd has scheduled a Board Meeting on July 28, 2026, to consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026. The trading window for dealing in securities of the company by Designated Persons and their immediate relatives is closed from July 1, 2026, and will remain closed till 48 hours after the results are made public.

Read more →📎 1 attachment
BSECompany Update23 Jun 2026

RPG Life Sciences Ltd

Newspaper publication

RPG Life Sciences Ltd has announced the publication of newspaper advertisements to inform stakeholders about its 19th Annual General Meeting (AGM). The AGM is scheduled to be held on Thursday, July 23, 2026, at 3:00 p.m. (IST) via Video Conferencing/Other Audio Visual Means. This disclosure is made in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and other relevant circulars.

Read more →📎 1 attachment